Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PPQK | ISIN: US4495851085 | Ticker-Symbol: 1K0
Frankfurt
24.04.25
16:02 Uhr
1,220 Euro
+0,040
+3,39 %
1-Jahres-Chart
IGM BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
IGM BIOSCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,0101,06018:39
1,2001,21018:41

Aktuelle News zur IGM BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08.04.IGM Biosciences slips as Bank of America downgrades on liquidity concerns3
IGM BIOSCIENCES Aktie jetzt für 0€ handeln
07.03.Stifel maintains IGM Biosciences stock hold with $2.50 target5
06.03.IGM Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
06.03.IGM Biosciences, Inc. - 10-K, Annual Report1
10.01.IGM Bio plunges as Wall Street downgrades on portfolio shakeup14
10.01.IGM Biosciences halts development of auto-immune treatments, shares plummet19
09.01.IGM Biosciences Halts Development Of Imvotamab, IGM-2644; To Lay Off 73% Of Workforce7
09.01.IGM Biosciences cuts workforce, halts a couple of product developments7
09.01.IGM Biosciences, Inc.: IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs171- Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) - - Company reducing its workforce by 73% - - Cash and investments of $183.8 million (unaudited) as of December...
► Artikel lesen
08.11.24IGM Biosciences, Inc.: IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update175- Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 - - IGM-2644 (CD38 x CD3) expected to enter...
► Artikel lesen
08.11.24IGM Biosciences, Inc. - 8-K, Current Report-
08.11.24IGM Biosciences, Inc. - 10-Q, Quarterly Report-
01.10.24Pre-market Movers: Shattuck Labs, SITE Centers, IGM Biosciences, ATIF Holdings, Arqit Quantum781OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.45 A.M. ET).In the Green SITE Centers Corp. (SITC) is up over 53% at $18.12. ATIF...
► Artikel lesen
30.09.24IGM Biosciences, Inc.: IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity329- Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus - - Mary...
► Artikel lesen
14.08.24IGM Biosciences, Inc.: IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update193- Enrollment complete in aplitabart randomized colorectal cancer clinical trial; top-line PFS results expected by the end of 1Q25 - - Second dose cohort cleared in imvotamab rheumatoid arthritis...
► Artikel lesen
08.05.24IGM Biosciences, Inc.: IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update177- Enrollment target exceeded in aplitabart randomized colorectal cancer clinical trial - - Enrollment completed in first dose cohort in imvotamab rheumatoid arthritis clinical trial - MOUNTAIN VIEW...
► Artikel lesen
16 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1